Abstract: Objective To understand non-small cell lung cancer（NSCLC）epidermal growth factor receptor （EGFR） mutations in Shenzhen,and to provide a basis for target therapy of NSCLC patients. Methods collected from March 2013 to November 2015 in shenzhen area three level 3 district hospital,One hundred and three cases of NSCLC cancer tissues were collected in 3 hospitals from 2013 to 2015,and DNA was extracted followed by detections of EGFR gene mutation in exon 18,19,20 and 2l using mutations specific amplification system （ARMS） amplification. Results All of 103 cases of NSCLC showed an EGFR gene mutation rate of 38.8% （40/103）,among them 18,19,20 and 21 exon mutations rates were 2.5%（1/40）,35.0%（14/40）,5.0%（2/40）,and 57.5%（23/40）,respectively. EGFR mutation rate was 48.7% （37/76）in patients with adenocarcinoma,higher than 11.1%（3/27）in the patients with non-adenocarcinoma.（χ²=25.617,P<0.01）. EGFR mutation rate in NSCLC patients of nonsmookers was 56.1% （32/57）,significantly higher than the smooker patients（ 17.4%,8/46） （χ²=20.195,P<0.01）. The mutation rate in female patients was 52.4%（22/42）,higher than that of the male （29.5%,18/61）（χ²=5.127,P<0.05）. The patients below 56 years exhibited an EGFR mutation rate of 39.5% （17/43）,compared to those over 56 years （38.3%,23/60）（χ²=0.618,P>0.618）.Conclusion EGFR mutations in NSCLC patients are mainly composed of exon 21,followed by exon19. Adenocarcinoma,femal,and nonsmoker patients seem to be the risk factors of EGFR gene mutation.

Key words: Non-small cell lung cancer, Epidermal growth factor receptor, Gene mutations